Video

VIDEO: HOPE-3 bolsters primary prevention in intermediate-risk patients


 

AT ACC 16

References

CHICAGO – Results from the HOPE-3 trial confirm what guidelines have already recommended: patients with intermediate risk for cardiovascular disease should be treated for primary prevention of coronary event, Dr. Prakash Deedwania said in an interview at the annual meeting of the American College of Cardiology.

In the Heart Outcomes Prevention Evaluation (HOPE)-3 trial, nearly 13,000 intermediate-risk men and women with no baseline cardiovascular disease were randomized to either lipid lowering with rosuvastatin at 10 mg/day or placebo, dual-antihypertensive therapy with candesartan plus chlorothiazide or placebo regardless of baseline blood pressure, or all three drugs or placebo. After a median of 5.6 years, the combined-therapy group had a 29% reduction in the composite of cardiovascular death or nonfatal MI or stroke, compared with placebo-treated controls, regardless of baseline LDL-cholesterol level. However, only subjects with a baseline pressure of greater than 143.5 mm Hg benefited from the dual-antihypertensive therapy.

In a video interview, Dr. Deedwania, professor of medicine at the University of California, San Francisco, Fresno, gave three takeaways from the HOPE-3 trial regarding primary prevention of cardiovascular events in patients at intermediate risk, how the results of the dual-antihypertensive treatment arm match up to guidelines, and whether there’s a future for the polypill.

Dr. Deedwania has received consultant fees and/or honoraria from Amgen, Pfizer, and Sanofi.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

chackett@frontlinemedcom.com

Recommended Reading

High-dose vitamin D improves heart structure, function in chronic heart failure
MDedge Family Medicine
Incretin-based diabetes drugs don’t raise heart failure risk
MDedge Family Medicine
FDA adds safety warnings to certain type 2 diabetes medications
MDedge Family Medicine
Similarities seen in rate and rhythm control for postsurgical AF
MDedge Family Medicine
Early antiarrhythmic drugs boost survival in shock-refractory cardiac arrest
MDedge Family Medicine
Stem cells show heart failure benefits in phase II trial
MDedge Family Medicine
FDA approves first leadless pacemaker
MDedge Family Medicine
USPSTF updates guideline for preventive aspirin therapy
MDedge Family Medicine
Drug-eluting stent recipients can safely have surgery sooner
MDedge Family Medicine
Standard incubation can miss P. acnes in infective endocarditis
MDedge Family Medicine